Atlas Trials

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Clinical trial NCT05734495 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05734495
Sponsor
Dana-Farber Cancer Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Waldenstrom Macroglobulinemia
Start date
2023-05-02
Primary completion
2029-01-25
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.